# AI in the oncology clinic: from narrow cleared tools to multimodal decision support

Source: https://onco.cc/roadmaps/ai-oncology-clinic/  
OnCo record `ai-oncology-clinic` (Roadmap). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

How AI is moving from single-task readers of scans and slides towards systems that weigh everything about a patient, and what regulators and evidence still require.

## Summary

Hundreds of narrow AI devices are cleared, mostly in radiology triage and screening. The first predictive pathology tools (ArteraAI) prove that AI can change treatment decisions under regulation. Foundation models promise breadth, but the evidence base for deployment, the regulatory framework for updating models, and reimbursement are all unsettled.

## Fields

- Kind: Roadmap
- Last checked: 2026-09-08

## Sources

- MASAI: AI-supported mammography screening finds more cancers with half the radiologist workload (Lancet Oncology 2023): https://doi.org/10.1016/S1470-2045(23)00298-X

## Connected records

- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/)
- technologies: [AI in radiology](https://onco.cc/technologies/radiology-ai-screening/), [AI trial matching & clinical decision support](https://onco.cc/technologies/ai-trial-matching/), [Atlas (Aignostics, Mayo Clinic, Charité)](https://onco.cc/technologies/atlas-aignostics/), [Digital pathology & AI](https://onco.cc/technologies/digital-pathology-ai/), [Foresight (generative EHR model)](https://onco.cc/technologies/foresight-ehr/), [Mammography & tomosynthesis](https://onco.cc/technologies/mammography/), [Med-Gemini and MedLM (Google)](https://onco.cc/technologies/med-gemini/), [Mirai (MIT breast cancer risk from mammograms)](https://onco.cc/technologies/mirai/), [MUSK (Stanford, vision-language pathology)](https://onco.cc/technologies/musk/), [Pathology & radiology foundation models](https://onco.cc/technologies/pathology-foundation-model/), [Prov-GigaPath (Microsoft, Providence)](https://onco.cc/technologies/prov-gigapath/), [Sybil (MIT/MGH lung cancer risk from CT)](https://onco.cc/technologies/sybil/), [Tempus multimodal models](https://onco.cc/technologies/tempus-multimodal/), [TITAN (whole-slide multimodal model)](https://onco.cc/technologies/titan/), [Virchow / Virchow2 (Paige, MSK)](https://onco.cc/technologies/virchow/)
- drugs: [ArteraAI Breast](https://onco.cc/drugs/artera-ai-breast/), [ArteraAI Prostate](https://onco.cc/drugs/artera-ai-prostate/)
- companies: [Paige AI](https://onco.cc/companies/paige/)
- ideas: [Patient-level multimodal foundation models for treatment selection](https://onco.cc/ideas/idea-multimodal-foundation-model/)
- collections: [Flatiron Health and Foundation Medicine Clinico-Genomic Database](https://onco.cc/collections/flatiron-foundation-cgdb/), [NCI Imaging Data Commons (IDC)](https://onco.cc/collections/imaging-data-commons/)
- roadmaps: [AI in oncology roadmap: pattern readers → foundation models → agents in the workflow](https://onco.cc/roadmaps/ai-oncology-roadmap/), [Diagnostics roadmap: stains → gene panels → blood tests that decide treatment](https://onco.cc/roadmaps/diagnostics-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/ai-oncology-clinic.json